Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-11
2007-09-11
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S567000, C514S663000, C514S741000, C514S905000, C514S909000
Reexamination Certificate
active
10886156
ABSTRACT:
The comprehensive pharmacologic therapy for treatment of obesity including Cysteine is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, Cysteine, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.
REFERENCES:
patent: 3097947 (1963-07-01), Kemmerer
patent: 4237118 (1980-12-01), Howard
patent: 4377595 (1983-03-01), Wurtman
patent: 4397866 (1983-08-01), Wurtman
patent: 5019594 (1991-05-01), Wurtman et al.
patent: 5084007 (1992-01-01), Malin et al.
patent: 5189064 (1993-02-01), Blum et al.
patent: 5480657 (1996-01-01), Allen
patent: 5527788 (1996-06-01), Svec et al.
patent: 5650438 (1997-07-01), Meier et al.
patent: 5795895 (1998-08-01), Anchors
patent: 5939076 (1999-08-01), Allocca
patent: 5977076 (1999-11-01), Anderson et al.
patent: 5977099 (1999-11-01), Nickolson
patent: 6048728 (2000-04-01), Inlow et al.
patent: 6207699 (2001-03-01), Rothman
patent: 6261589 (2001-07-01), Pearson et al.
patent: 6323236 (2001-11-01), McElroy
patent: 6335323 (2002-01-01), Worsley
patent: 6384088 (2002-05-01), Hinz
patent: 6403657 (2002-06-01), Hinz
patent: 6548551 (2003-04-01), Hinz
patent: 6660777 (2003-12-01), Hinz
patent: 6759437 (2004-07-01), Hinz
patent: 2001/0002269 (2001-05-01), Zhao
patent: 2001/0008641 (2001-07-01), Krotzer
patent: 2001/0008884 (2001-07-01), Worsley
patent: 2001/0020007 (2001-09-01), Wiss
patent: 2002/0040054 (2002-04-01), Hinz
patent: 2002/0147206 (2002-10-01), Howard, Jr.
patent: 2002/0187958 (2002-12-01), Horrobin et al.
patent: 2003/0181509 (2003-09-01), Hinz
patent: 2004/0071681 (2004-04-01), Muller
patent: 2004/0077556 (2004-04-01), Chinery
patent: 2004/0081678 (2004-04-01), Cincotta
patent: 2004/0101575 (2004-05-01), Hinz
patent: 2004/0116351 (2004-06-01), Halevie-Goldman
patent: 2004/0151771 (2004-08-01), Gin et al.
patent: 2004/0229285 (2004-11-01), Hinz
patent: 2004/0247669 (2004-12-01), Gin et al.
patent: 2005/0065190 (2005-03-01), Hinz
patent: 2005/0233008 (2005-10-01), Hinz
patent: 2005/0233014 (2005-10-01), Lee et al.
patent: 2005/0287226 (2005-12-01), Sisco et al.
patent: 0347066 (1989-12-01), None
patent: 2137493 (1984-10-01), None
patent: 410067663 (1998-03-01), None
patent: 01/26642 (2001-04-01), None
Heath, “Pulmonary Vascular Disease” Medical Clinics of North America vol. 61(6), pp. 1279-1307 (1997).
Hirsch, “The Treatment of Obesity with Drugs” The American Journal of Clinical Nutrition, pp. 2-4, (Jan. 1998).
San Juan, Puerot Rico, Dec. 15, 2000 “PRNewswire”.
Brain ResJun. 12, 1999;831 (1-2):229-36, Transport mechanisms for the antidepressant citalopram in brain microvessal endothelium; written by B. Rochat, P. Baumann, KL Andus.
Psychomharmacol Bull1997;33(1):109-12, Plasma levels of citalopram enantiomers and metabolites in elderly patients; written by JP Foglia, BG Pollock, MA Kirshner, J Rosen, R Sweet, and B Mulsant.
Abstract from:Clin NeuropharmacolMar.-Apr. 2000;23(2):90-7; Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors; written by BH Harvey and CD Bower.
Abstract from:Clin Psychiatry2000;61 Suppl 11(1-2):37-41, Weight gain and antidepressants; M Fava.
Abstract from:J Clin PsychiatryNov. 2000;61(11):863-7, Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment; written by M Fava, R Judge, SL Hoog, ME Nilsson, and SC Koke.
Abstract from:Int clin psychopharmacolNov. 1999; 14(6):329-37; Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group; written by E Leinonen, J Skarstein, K Behnke, H Agren, and JT Helsdingen.
Excerpt from:Anchors(US Patent 5,795,895)book, “Safer than Phen-fen”, p. 82; written by Michael Anchors, M.D., Ph.D., Aug. 1998.
Budavari et al.,The Merck Index, 1989, Merck & Co., Inc., 11thEdition, pp. 2321 and 4116.
Riley et al.,Facts and Comparisons®, 1999, pp. 239, 264(d), and 264(td).
The Medical Clinics of North America, vol. 61/No. 6, Nov. 1977; Pulmonary Vascular Disease, written by Donald Heath and Paul Smith, pp. iii and 1279-1307.
The American Journal of Clinical Nutrition, Jan. 1998—vol. 67—No. 1; Treatment of Obesity with Drugs; written by Jules Hirsch.
Archives of Internal Medicine, Jan. 12, 1998, vol. 158, p. 102; Asymptomatic Mitral and Aortic Valve Disease Is Seen in Half of the Patients Taking ‘Phen-Fen’; written by Griffen et al.
The Medical Letter® On Drugs and Therapeutics, vol. 36 (Issue 936), Nov. 25, 1994, pp. 107-108; Fluoxetine (Prozac) and Other Drugs for Treatment of Obesity.
Archives of Internal Medicine, May 11, 1998, vol. 158, pp. 1278-1279; The “Phen-Pro” Diet Drug Combination is Not Associated With Valvular Heart Disease; written by Griffen et al.
Deposition Transcripts of Dr. Martin C. Hinz (vol. I of Nov. 17, 2004; and vol. II of Feb. 24. 2005).
Deposition Transcripts of Gottfried Kellermann, which is also on behalf of Neuroscience (vol. I of Nov. 23, 2004; and vol. II of Nov. 24, 2004).
Deposition Transcript of Dr. William Wilson—Nov. 12, 2004.
Deposition Transcript of Dave Peterson—Feb. 28, 2005.
Abell et al., “Placebo Controlled Double-Blind Trial of Fluvoxamine Maleate in the Obese”,Journal of Psychosomatic Research, 30(2): 143-164 (1986).
Bouchard et al. “Gitalopram and Viloxazine in the treatment of depression by means of slow drop infusion A double-linked comparative trial”,Journal of Affective Disorders, 46:51-58 (1997).
Marek et al., “A comparison of trazodone and fluoxetine: implications for serotonergic mechanis of antidepressant action”,Psychopharmacology109:2-11 (1992).
Van Praag, “In Search of the Mode of Action of Antidepressants 5-HTP/Tyrosine Mixtures in Depressions”, Neuropharmacology 22(38):443-440 (1983).
U.S. Appl. No. 09/523,114, filed Mar. 10, 2000, Hinz.
U.S. Appl. No. 11/282,965, filed Nov. 18, 2005, Hinz.
U.S. Appl. No. 11/353,644, filed Feb. 14, 2006, Hinz.
U.S. Appl. No. 11/353,643, filed Feb. 14, 2006, Hinz.
Agundez et al, “Modulation of CyP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine”,Pharmacogentics, 8:251-258 (1998).
Andrews et al, “The Effects of 5-hydraoxytryptophan and 5-hydroxytryptamine on Dopamine Synthesis and Release in Rat Brain Striatal Synaptosomes”,Journal of Neurochemistry, 30:465-470 (1978).
Avarello, “Serotonin Syndrome: a reported case”,Neuro Sci, 23:S55-S56 (2002).
Bartholome et al., “L-dopa and 5-hydroxytryptophan Therapy in Phenylalanine-Hydroxylase Activity”,The Lancet2(Nov. 22): 1042-1043 (1975).
Bouyer et al., “Modification of Spontaneous ECoG and Behavior in Cat by Monoamine Precursors”,Psychopharmacology, 65:49-54 (1979).
Coppen et al. “Levodopa and L-tryptophan Therapy in Parkinsonism”,The Lancet, Mar. 25, (1972).
Dunner et al., “Affective Disorder: Studies with Amine Precursors”,Am J. Psychiatry, 132(2):180-183 (1975).
Gelenberg et al. “Tyrosine for the treatment of depression”,Nutr. Health, 3(3):163-73 (1984).
Hurley et al., Pyrrolo [1,4]benzodiazepine Antibiotics. Biosynthesis of the Antitumr Antibiotic 11-Demethyltomaymycin and its Biologically Inactive metabolity Oxotomaymycin to Streptomyces achromogene,Biochemistry, 15(17):3760-3769 (1976).
Kramarcy et al, “Effects of Drug-Inducted Changes in Brian Monoamines on Ag
Kim Vickie
Patterson Thuente Skaar & Christensen P.A.
LandOfFree
Comprehensive pharmacologic therapy for treatment of obesity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Comprehensive pharmacologic therapy for treatment of obesity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Comprehensive pharmacologic therapy for treatment of obesity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3747727